Cibus (CBUS) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Cibus Days Payable?

Cibus's average Accounts Payable for the three months ended in Mar. 2024 was $6.40 Mil. Cibus's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Cibus's Days Payable or its related term are showing as below:

During the past 9 years, Cibus's highest Days Payable was 603.16. The lowest was 10.42. And the median was 37.27.

CBUS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

Cibus's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Cibus Days Payable Historical Data

The historical data trend for Cibus's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cibus Days Payable Chart

Cibus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

37.27

10.42

13.99

Cibus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cibus's Days Payable

For the Biotechnology subindustry, Cibus's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cibus's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's Days Payable distribution charts can be found below:

* The bar in red indicates where Cibus's Days Payable falls into.

Cibus Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Cibus's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.34	+	6.127)	/	2 )	/	0	*	365
=	3.2335					/	0	*	365
=	N/A

Cibus's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (6.127	+	6.672)	/	2 )	/	0	*	365 / 4
=	6.3995					/	0	*	365 / 4
=	N/A

Cibus Days Payable Related Terms

Thank you for viewing the detailed overview of Cibus's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cibus (CBUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

6455 Nancy Ridge Drive, San Diego, CA, USA, 92121

Website

https://www.cibus.com

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.

Executives

Rory B Riggs	director, officer: Chief Executive Officer	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr.	director	1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn	10 percent owner	C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante	director	SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn	director	VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann	director	21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker	director	13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King	officer: Chief Financial Officer	750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William	officer: See Remarks	13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham	director, officer: See Remarks	6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill	director	C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr	director, officer: President and CEO	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak	officer: Chief Financial Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter	officer: Chief Business Officer	202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas	officer: Chief Science Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113